Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis (NCT07474792)
A Multicenter, Randomized, Double-Blinded, Placebo- Controlled, Dose-Range Finding Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ORKA-002 in Participants With Moderate-to-Severe Plaque Psoriasis
🩺 Plain-English Summary (8th-Grade Level)
This is a multicenter, randomized, double-blinded, placebo-controlled, dose-range finding study to evaluate the efficacy and safety of ORKA-002 in adult participants with moderate-to-severe plaque psoriasis.
Who can join: Review the eligibility criteria below.
Location: Oruka Therapeutics Investigative Site — Birmingham, Alabama
Age range: 18 Years to 79 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (39 Sites)
Showing the first 25 of 39 sites.
- Oruka Therapeutics Investigative Site — Birmingham, Alabama
- Oruka Therapeutics Investigative Site — Phoenix, Arizona
- Oruka Therapeutics Investigative Site — Fountain Valley, California
- Oruka Therapeutics Investigative Site — Los Angeles, California
- Oruka Therapeutics Investigative Site — San Diego, California
- Oruka Therapeutics Investigative Site — Santa Ana, California
- Oruka Therapeutics Investigative Site — Santa Monica, California
- Oruka Therapeutics Investigative Site — Cromwell, Connecticut
- Oruka Therapeutics Investigative Site — Miami, Florida
- Oruka Therapeutics Investigative Site — Rolling Meadows, Illinois
- Oruka Therapeutics Investigative Site — Boston, Massachusetts
- Oruka Therapeutics Investigative Site — Milford, Massachusetts
- Oruka Therapeutics Investigative Site — Ann Arbor, Michigan
- Oruka Therapeutics Investigative Site — Detroit, Michigan
- Oruka Therapeutics Investigative Site — Warren, Michigan
- Oruka Therapeutics Investigative Site — New Brighton, Minnesota
- Oruka Therapeutics Investigative Site — Omaha, Nebraska
- Oruka Therapeutics Investigative Site — Elmhurst, New York
- Oruka Therapeutics Investigative Site — New York, New York
- Oruka Therapeutics Investigative Site — Wilmington, North Carolina
- Oruka Therapeutics Investigative Site — Bexley, Ohio
- Oruka Therapeutics Investigative Site — Portland, Oregon
- Oruka Therapeutics Investigative Site — Warrenton, Oregon
- Oruka Therapeutics Investigative Site — Charleston, South Carolina
- Oruka Therapeutics Investigative Site — Dallas, Texas
📞 Contact the Study Coordinator
Phone: (781) 560-0299
Email: clinicaltrials@orukatx.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Plaque Psoriasis
- A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis — Phoenix, Arizona
- Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis — Phoenix, Arizona
- A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis — Birmingham, Alabama
- Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects — Rogers, Arkansas
- Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis — Birmingham, Alabama
- A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2) — Phoenix, Arizona
Explore by condition: All Plaque Psoriasis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.